Another strategy is to combine the anti-EGFR mAb panitumumab with an anti-hepatocyte growth factor mAb rilotumumab (252) or ganitumab (230), an anti-insulin-like growth factor 1 receptor (IGF-1R) mAb in metastatic colorectal cancer with wild-type KRAS (NCT00788957) (328). Here, KRAS is linked to metastatic colorectal cancer.